Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$2.17 USD

2.17
1,003,269

-0.09 (-3.98%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $2.14 -0.03 (-1.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

GE HealthCare (GEHC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

Zacks Equity Research

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.

Zacks Equity Research

Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.

Zacks Equity Research

All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Novartis (NVS) Announces Positive Long-Term Data on Leqvio

by Zacks Equity Research

Novartis (NVS) Leqvio shows consistent efficacy and safety beyond six years in patients with ASCVD.

Zacks Equity Research

Bristol Myers (BMY) Gets FDA Nod for Reblozyl Label Expansion

by Zacks Equity Research

Bristol Myers' (BMY) Reblozyl is now indicated in the United States as the first-line treatment of anemia in adults with lower-risk MDS who may require transfusions.

Zacks Equity Research

New Strong Buy Stocks for August 29th

by Zacks Equity Research

SPRO, FBIZ, KNSL, BMI and FDUS have been added to the Zacks Rank #1 (Strong Buy) List on August 29, 2023.

Zacks Equity Research

Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar

by Zacks Equity Research

Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.

Zacks Equity Research

Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive

by Zacks Equity Research

Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.

Zacks Equity Research

Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment

by Zacks Equity Research

Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.

Zacks Equity Research

Bristol Myers' (BMY) Opdivo Gets EC Nod for Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) obtains approval in the EU for Opdivo for the adjuvant treatment of adults and adolescents with stage IIB or IIC melanoma who have undergone complete resection.

Zacks Equity Research

Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold

by Zacks Equity Research

Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.

Zacks Equity Research

Novartis (NVS) Plans to Spin-Off Sandoz in Early October

by Zacks Equity Research

Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.

Zacks Equity Research

Regeneron's (REGN) Application for Blood Cancer Drug Accepted

by Zacks Equity Research

Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.

Zacks Equity Research

Bristol Myers (BMY) Announces Positive Updated NSCLC Data

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer.

Zacks Equity Research

Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies

by Zacks Equity Research

Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.

Zacks Equity Research

Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%

by Zacks Equity Research

Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 20.69% and 23.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 4.11% and 77.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 89.47% and 42.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of 4.29% and 18.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength?

by Zacks Equity Research

TELA Bio, Inc. (TELA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich

by Zacks Equity Research

Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.